Stimulan

01Pathophysiology

Stimulants exert their effects by augmenting catecholamine and serotonin signaling in the central and peripheral nervous systems. The two prototypical agents tested on exams are cocaine and amphetamines, and although they share a final common pathway of excessive monoamine activity, their mechanisms differ in an important and testable way.

Cocaine acts primarily as a reuptake inhibitor at the dopamine, norepinephrine, and serotonin transporters (DAT, NET, SERT). By blocking the presynaptic transporter, cocaine prevents clearance of these neurotransmitters from the synaptic cleft, leading to prolonged receptor stimulation. Cocaine also blocks voltage-gated sodium channels, which accounts for its local anesthetic properties and its propensity to cause cardiac arrhythmias (it essentially behaves like a Class I antiarrhythmic at toxic levels, widening QRS complexes). Additionally, cocaine promotes coronary artery vasospasm through alpha-1 adrenergic stimulation and enhances platelet aggregation, which together explain why a 25-year-old with no cardiac risk factors can present with an acute myocardial infarction.

Amphetamines (including methamphetamine) work through a different mechanism: they enter the presynaptic neuron via monoamine transporters and reverse the direction of the transporter, causing a flood of dopamine, norepinephrine, and serotonin into the synapse. They also inhibit monoamine oxidase (MAO) and vesicular monoamine transporter (VMAT), displacing stored neurotransmitters from vesicles into the cytoplasm and then into the synapse. The net result is a more sustained and prolonged sympathomimetic surge compared to cocaine, which is why amphetamine intoxication tends to last longer.

The euphoria and reward seen in intoxication are driven by dopamine release in the nucleus accumbens (the mesolimbic pathway). The psychosis and paranoia seen at higher doses result from excessive dopaminergic activity in the mesolimbic and mesocortical pathways. The peripheral sympathomimetic effects (tachycardia, hypertension, mydriasis, diaphoresis, hyperthermia) are mediated by excess norepinephrine acting on alpha and beta adrenergic receptors.

Withdrawal occurs because chronic stimulant use leads to downregulation of postsynaptic dopamine receptors and depletion of presynaptic dopamine stores. When the drug is abruptly discontinued, the brain enters a state of relative dopamine deficiency, producing the characteristic "crash" of profound fatigue, hypersomnia, increased appetite, and dysphoric mood. Unlike alcohol or benzodiazepine withdrawal, stimulant withdrawal is not medically dangerous and does not produce seizures or autonomic instability on its own. This distinction is a frequent test point.

02Classification and Clinical Manifestation

Stimulant Intoxication

Stimulant Withdrawal

Severity Spectrum of Intoxication

03Diagnostic Workup

The diagnostic approach to stimulant intoxication is largely clinical, based on the constellation of sympathomimetic signs (tachycardia, hypertension, mydriasis, agitation, diaphoresis) combined with the history. A urine drug screen serves as the best initial test to confirm exposure, but treatment should never be delayed while awaiting results. It is important to note that a positive UDS confirms recent exposure but does not confirm acute intoxication, since cocaine metabolites can persist for days.

An ECG is essential in any patient presenting with stimulant-related chest pain. In cocaine toxicity, look for ST-segment elevations (indicating ischemia from vasospasm or thrombosis) and QRS widening (indicating sodium channel blockade). If the ECG shows ischemic changes, troponin levels should be drawn serially.

CK levels should be obtained in any patient with prolonged agitation, hyperthermia, or seizures, as rhabdomyolysis is a common and potentially lethal complication. A CK greater than five times the upper limit of normal with myoglobinuria confirms the diagnosis.

For patients with focal neurologic deficits or persistent altered mental status, a non-contrast CT of the head should be obtained promptly to evaluate for hemorrhagic stroke, which is more common with amphetamine use due to severe hypertensive surges.

For withdrawal, the diagnosis is entirely clinical. There is no confirmatory test. The key diagnostic feature is the temporal relationship: a patient who was recently bingeing on stimulants now presents with the opposite symptom profile (hypersomnia, increased appetite, depressed mood, psychomotor slowing) with normal vital signs.

04Management and Treatment

Intoxication Management

Withdrawal Management

Benzodiazepines are the cornerstone of acute stimulant intoxication management. They address agitation, seizures, hypertension, and tachycardia simultaneously by reducing central sympathetic outflow. The examiner will test whether you reach for benzodiazepines first rather than antipsychotics or antihypertensives.

The single most tested treatment pearl in stimulant toxicology is the avoidance of beta-blockers in cocaine intoxication. The rationale: cocaine stimulates both alpha and beta adrenergic receptors. If you block only the beta receptors (vasodilation, cardiac chronotropy), you leave alpha-mediated vasoconstriction unopposed, which can paradoxically worsen hypertension and precipitate coronary vasospasm. This is why labetalol (a combined alpha-beta blocker) remains controversial in this setting, and pure beta-blockers like propranolol and metoprolol are strictly contraindicated. If blood pressure remains elevated despite benzodiazepines, use phentolamine (a pure alpha-blocker), nicardipine, or nitroprusside.

For cocaine-associated myocardial infarction, the management mirrors standard ACS protocols with important modifications: administer benzodiazepines, aspirin, nitroglycerin, and consider calcium channel blockers. If the patient meets criteria for STEMI, proceed with percutaneous coronary intervention (PCI). Do not give beta-blockers. Fibrinolytics should be used with caution given the hypertensive state.

For cocaine-induced wide QRS complex or ventricular arrhythmias, administer sodium bicarbonate to counteract the sodium channel blockade. This is analogous to its use in tricyclic antidepressant toxicity.

Stimulant withdrawal management is entirely supportive. There is no reversal agent or taper protocol. The "crash" is self-limited and resolves within 1 to 2 weeks. The primary concern during withdrawal is suicidality secondary to profound depression, so psychiatric assessment is warranted. No medication has been proven effective for stimulant withdrawal or long-term maintenance therapy (unlike naltrexone for alcohol or methadone/buprenorphine for opioids). Behavioral interventions, particularly contingency management, have the strongest evidence for sustaining abstinence.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on stimulant questions is by confusing the toxidromes. The critical distinction between sympathomimetic and anticholinergic toxidromes rests on a single physical exam finding: skin moisture. Stimulant intoxication produces diaphoresis (wet skin) because sympathetic activation stimulates eccrine sweat glands. Anticholinergic toxicity produces dry skin because muscarinic blockade inhibits those same glands. When a vignette describes a tachycardic, mydriatic, agitated patient, immediately look for whether the skin is described as "flushed and dry" or "diaphoretic."

The second major trap is selecting a beta-blocker for cocaine-induced hypertension or chest pain. This is one of the most commonly tested "wrong answer" choices. Even labetalol, which has both alpha and beta blocking activity, is considered incorrect in the standard exam framework. The examiners are testing whether you understand the concept of "unopposed alpha stimulation." The correct answer for refractory hypertension in cocaine toxicity is benzodiazepines first, followed by phentolamine or a calcium channel blocker.

A third trap involves stimulant withdrawal. Students often assume that withdrawal from any substance is dangerous and requires pharmacologic intervention. The exam tests your understanding that stimulant withdrawal, while deeply unpleasant, is not medically life-threatening and has no validated pharmacologic treatment. The vignette will describe a patient with profound fatigue, increased sleep, increased appetite, and depressed mood after a cocaine or methamphetamine binge, and the correct management is supportive care. Do not select antidepressants for acute withdrawal management. The main concern warranting clinical attention is the risk of suicidal ideation during the depressive phase.

Finally, be alert to the MDMA-hyponatremia question. A young patient at a music festival or club who presents with seizures or altered mental status after taking ecstasy should prompt consideration of dilutional hyponatremia from SIADH combined with excessive free water intake, rather than (or in addition to) hyperthermia. The treatment is hypertonic saline if symptomatic, not just cooling.

The core competency being tested across all stimulant questions is your ability to recognize a sympathomimetic toxidrome by its physical exam findings, distinguish it from look-alike syndromes using one or two key discriminators, and select the correct pharmacologic intervention while avoiding the well-established contraindications.